Comparative Pharmacology
Head-to-head clinical analysis: ATROPINE SULFATE versus PAMINE FORTE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATROPINE SULFATE versus PAMINE FORTE.
ATROPINE SULFATE vs PAMINE FORTE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of muscarinic acetylcholine receptors (M1, M2, M3, M4, M5), blocking the effects of acetylcholine at parasympathetic postganglionic junctions. Increases heart rate, reduces exocrine secretions, relaxes smooth muscle in GI and GU tracts, and dilates pupils.
Anticholinergic agent; competitively blocks acetylcholine at muscarinic receptors, reducing gastrointestinal motility and secretory activity.
0.5 to 1 mg intravenously or intramuscularly every 3 to 5 minutes as needed, up to a total of 3 mg (3 doses) for bradycardia; 0.5 to 1 mg subcutaneously, intramuscularly, or intravenously every 4 to 6 hours for antisecretory effects; 1 to 2 mg intravenously every 5 minutes for organophosphate poisoning.
1 tablet (5 mg) orally 4 times daily, before meals and at bedtime.
None Documented
None Documented
Terminal elimination half-life approximately 2-4 hours in adults; prolonged in elderly and infants; clinically significant due to potential accumulation with repeated dosing.
1.5-2 hours; prolonged in renal impairment
Renal excretion of unchanged drug and metabolites; ~50% excreted unchanged in urine; remainder as inactive metabolites (tropine, tropic acid); biliary/fecal excretion minor.
Renal (70% unchanged), biliary/fecal (30%)
Category C
Category C
Anticholinergic Agent
Anticholinergic Agent